"Won't GLP-1 medications cause pancreatitis? and cancer?"
A meta-analysis of serious adverse events in earlier GLP-1s (Exenatide and Liraglutide) across 25 studies found no increase in OR (odds ratio) for thyroid cancer or acute pancreatitis
Patients taking this weight loss drug lost more than 50 pounds, and experts say this drug could be a good replacement for bariatric surgery! Read more here:
Twin and family studies have shown genetics can contribute to 40-70% of obesity. We have to use genetic and physiologic mechanisms to control body weight.
This article from vogue details the struggle of going to the doctors office when dealing with obesity. The stigma against obese people in healthcare is real and has to be taken more seriously.
The reported rate of obesity among US adolescents is higher than in the past, and this article shows how there could be a correlation with socioeconomic status.
Those with larger bodies are both more likely to be dismissed for major health concerns and less likely to seek medical care at all. Read more about fatphobia in healthcare in this blog at the link in our bio.
#Semaglutide
and Cardiovascular outcomes in T2DM: 3183 patients 50+ yo
On Oral semaglutide vs placebo:
⬇️ 2 year mortality from cardiovascular causes
⬇️ 2 year mortality from any cause
↔️ no change in nonfatal MI/stroke,/heart failure
PIONEER 6:
A study of patients cared for by the Veterans Health Administration (VHA) showed that only 0.2% of more than 2 million patients who met NIH criteria for consideration of a weight-loss medication filled a prescription for one of these agents (9).
FDA has expanded access to prescription weight loss medication: Qsymia. Teens ages 12+ are now eligible for this medication which is a huge step to combat childhood obesity!
Quick and easy "solutions" are not just unsustainable, but risky. Changing your appetite requires careful and direct treatment over a period of time. With Mochi, we guide you through making sustainable lifestyle changes with our peer-group support network.
Eli-Lilly recently completed the SURMOUNT-1 trial, one of many planned trials for Tirzepatide, a new combination GLP-1/GIP medication for Type 2 Diabetes and Obesity. Between the data from this and the other SURPASS trials, this looks promising!
We are constantly bombarded by weight loss agents in the media that are supposedly “proven effective,” but are they really? Here we introduce some of these agents and break down the common myths about their effectiveness. Check it out on our blog: